SESN Investors Have Opportunity to Lead Sesen Bio, Inc. Securities Fraud Lawsuit

  • 31
SESN Investors Have Opportunity to Lead Sesen Bio, Inc. Securities Fraud Lawsuit
Investors with losses exceeding $250,000 are encouraged to contact the firm

PR Newswire

BENSALEM, Pa., Oct. 14, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ("Sesen Bio" or the "Company") (NASDAQ: SESN).

Class Period: December 21, 2020 - August 17, 2021
Lead Plaintiff Deadline: October 18, 2021

Investors suffering losses on their Sesen Bio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors: (1) that Sesen Bio's clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) that three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum; (4) that Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) that, as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum;  and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/sesn-investors-have-opportunity-to-lead-sesen-bio-inc-securities-fraud-lawsuit-301400751.html

SOURCE Law Offices of Howard G. Smith

PR Newswire

PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.